Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.
Computational Biological Center, IBM Thomas J. Watson Research, Yorktown Heights, NY 10598, USA.
Cell Rep. 2022 Sep 13;40(11):111359. doi: 10.1016/j.celrep.2022.111359. Epub 2022 Aug 29.
Despite being more transmissible, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant only causes milder diseases in laboratory animals, often accompanied by a lower viral load compared with previous variants of concern. In this study, we report the structural basis for a robust interaction between the receptor-binding domain of the Omicron spike protein and mouse ACE2. We show that pseudovirus bearing the Omicron spike protein efficiently utilizes mouse ACE2 for entry. By comparing viral load and disease severity among laboratory mice infected by a natural Omicron variant or recombinant ancestral viruses bearing either the entire Omicron spike or only the N501Y/Q493R mutations in its spike, we find that mutations outside the spike protein in the Omicron variant may be responsible for the observed lower viral load. Together, our results imply that a post-entry block to the Omicron variant exists in laboratory mice.
尽管严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的奥密克戎变体传播性更强,但它在实验动物中只会引起较轻的疾病,通常与之前的关注变体相比,病毒载量较低。在这项研究中,我们报告了奥密克戎刺突蛋白的受体结合域与小鼠 ACE2 之间强大相互作用的结构基础。我们表明,携带奥密克戎刺突蛋白的假病毒能够有效地利用小鼠 ACE2 进入细胞。通过比较由天然奥密克戎变体或携带奥密克戎刺突蛋白全长或仅 N501Y/Q493R 突变的重组原始病毒感染的实验小鼠中的病毒载量和疾病严重程度,我们发现奥密克戎变体中刺突蛋白以外的突变可能是导致观察到的较低病毒载量的原因。总之,我们的结果表明,实验小鼠中存在针对奥密克戎变体的进入后阻断。